Press Room

News / Jun 23, 2022

The Low Carbon Pledge

4th Annual Low Carbon Pledge Report

Green tree in front of Hovione R&D Center in Portugal. Hovione is a BITC Low Carbon Pledge signatory

Collaboration is key to achieving our climate goals.

Together with the Business in the Community Ireland Low Carbon Pledge, we continue to be committed to climate action as part of a movement of 70 businesses. Setting and working towards the achievement of science-based emissions reduction targets, together with peer-to-peer learning and collaboration, are some of the key actions we are taking to transition to a net-zero future.

Today the 4th Annual Low Carbon Pledge Report progress report was published sharing the steady progress of our collective movement.

Being part of this collective movement is strategic for Hovione Cork as we are committed to doing our part for a better world. As part of Hovione’s commitment to climate action, we are proud to be a Business in the Community Ireland Low Carbon Pledge signatory.

The Low Carbon Pledge is the first dedicated pledge generated by Irish businesses to set industry standards on sustainability and reduce carbon emissions. Originally launched in 2018, the Pledge has now evolved and calls on all Irish businesses to work collectively towards setting science-based targets and achieving our long-term climate goals of net-zero by 2050.

 

You can download a copy of the 4th Annual Low Carbon Pledge Report at BITC.ie

 

Find more about Sustainability at Hovione

 

 

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026